Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3607828 | 0.92 | AGTR1 (0.38) | AGTR1 | |
| SCHEMBL3601295 | 0.83 | AGTR1 (0.38) | AGTR1POLBSMN1; SMN2 | |
| SCHEMBL3328548 | 0.74 | AGTR1 (0.32) | AGTR1POLBSMN1; SMN2 | |
| SCHEMBL3329106 | 0.73 | PTGS2 (0.37) | AGTR1POLBSMN1; SMN2 | |
| SCHEMBL3326379 | 0.72 | AGTR1 (0.35) | AGTR1POLBSMN1; SMN2 | |
| SCHEMBL6047203 | 0.71 | PTGS2 (0.38) | — | |
| SCHEMBL3610158 | 0.71 | HSD17B1 (0.40) | AGTR1 | |
| SCHEMBL3328019 | 0.70 | MAPK14 (0.43) | POLBSMN1; SMN2 | |
| SCHEMBL3327277 | 0.70 | ALDH1A1 (0.33) | AGTR1SMN1; SMN2 | |
| SCHEMBL30743612 | 0.69 | ABCG2 (0.55) | AGTR1POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835476-B2 | Synthesis of novel antimicrobials | WU FAN (CA) | 2014-09-16 | — | — | US | disclosed |
| US-20100137388-A1 | Therapeutic Pro-Antibiotic Agents and Methods of Use Thereof | DENOVAMED INC. (CA) | 2010-06-03 | — | — | US | disclosed |
| US-20100076028-A1 | Design and Synthesis of Novel Antimicrobials | WU FAN | 2010-03-25 | — | — | US | disclosed |
| WO-2008128321-A1 | THERAPEUTIC PRO-ANTIBIOTIC AGENTS AND METHODS OF USE THEREOF | DENOVAMED INC. (CA) | 2008-10-30 | — | — | WO | disclosed |
| WO-2006092059-A1 | DESIGN AND SYNTHESIS OF NOVEL ANTIMICROBIALS | WU FAN (CA) | 2006-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076028-A1 | Design and Synthesis of Novel Antimicrobials | MLX, LPXN, TPX2 | AGTR1 912/4885POLB 1277/4885SMN1; SMN2 4868/4885 |
| US-20100137388-A1 | Therapeutic Pro-Antibiotic Agents and Methods of Use Thereof | NAT1, NAPEPLD, NR1I2 | AGTR1 2359/4885POLB 2264/4885SMN1; SMN2 3325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.